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Identification and Characterization of a Bacitracin Resistance Network
in Enterococcus faecalis
Susanne Gebhard,a Chong Fang,a Aishath Shaaly,b David J. Leslie,b Marion R. Weimar,b Falk Kalamorz,b* Alan Carne,c
Gregory M. Cookb
Department of Biology I, Microbiology, Ludwig-Maximilians-Universität München, Martinsried, Germanya; Department of Microbiology and Immunologyb and
Department of Biochemistry,c Otago School of Medical Sciences, University of Otago, Dunedin, New Zealand
Resistance of Enterococcus faecalis against antimicrobial peptides, both of host origin and produced by other bacteria of the gut
microflora, is likely to be an important factor in the bacterium’s success as an intestinal commensal. The aim of this study was to
identify proteins with a role in resistance against the model antimicrobial peptide bacitracin. Proteome analysis of bacitracin-
treated and untreated cells showed that bacitracin stress induced the expression of cell wall-biosynthetic proteins and caused
metabolic rearrangements. Among the proteins with increased production, an ATP-binding cassette (ABC) transporter with
similarity to known peptide antibiotic resistance systems was identified and shown to mediate resistance against bacitracin. Ex-
pression of the transporter was dependent on a two-component regulatory system and a second ABC transporter, which were
identified by genome analysis. Both resistance and the regulatory pathway could be functionally transferred to Bacillus subtilis,
proving the function and sufficiency of these components for bacitracin resistance. Our data therefore show that the two ABC
transporters and the two-component system form a resistance network against antimicrobial peptides in E. faecalis, where one
transporter acts as the sensor that activates the TCS to induce production of the second transporter, which mediates the actual
resistance.
Enterococcus faecalis is a member of the normal gut microflorain animals and humans. While it is mostly a harmless com-
mensal, opportunistic infections, particularly of immunocom-
promised hospital patients, are amajor health concern. Due to the
rise of vancomycin-resistant strains (VREs), treatment of such
infections is becoming increasingly difficult, and a better under-
standing of the resistance of E. faecalis against cell wall-targeting
antibiotics is urgently needed. In addition to vancomycin resis-
tance, enterococci display a high intrinsic resistance against other
inhibitors of cell wall biosynthesis, including cephalosporins and
bacitracin (1–3). Bacitracin is not used clinically for the treatment
of enterococcal infections, yet resistance against this and other
peptide antibiotics is nevertheless biologically relevant in the hu-
man intestinal environment. For example, gut bacteria are ex-
posed to defensins that are part of the innate immune defense in
the gastrointestinal tract (4). Additionally, other members of the
microflora, especially lactic acid bacteria, produce a range of bac-
teriocins as a means of interspecies competition (5). Thus, resis-
tance of E. faecalis against peptide antibiotics is likely to be impor-
tant for the success of the bacterium in the human host, which in
turn affects the risk of opportunistic infections.
In other Gram-positive bacteria, several resistance mecha-
nisms that combat the action of cell wall-active peptides have been
identified. One strategy can be alterations in the cell’s surface
charge, for example, by alanylation of teichoic acids catalyzed by
the DltABCD system (6, 7). Accordingly, in a recent study, the dlt
operon of E. faecalis was shown to be upregulated in response to
bacitracin and vancomycin (8). Alternatively, upregulation of the
enzyme inhibited by the antibiotic, e.g., in the case of bacitracin,
undecaprenyl-pyrophosphate phosphatases, can confer resis-
tance, as has been shown for Bacillus subtilis and E. faecalis (2, 9).
A third resistance mechanism is the expression of specific ATP-
binding cassette (ABC) transporters. One type of such transport-
ers possesses permeases with six transmembrane helices and is
exemplified by the bacitracin transporter BcrAB, which is used for
self-immunity by bacitracin-producing strains of Bacillus licheni-
formis (10) but has also been shown to confer acquired high-level
bacitracin resistance toE. faecalis (3). Anunrelated group of trans-
porters, characterized by permeases with 10 transmembrane heli-
ces and a large extracellular domain, are involved in resistance
against a range of antimicrobial peptides. The best-understood
example is BceAB of B. subtilis, which confers resistance against
bacitracin, mersacidin, and actagardine (11, 12). These transport-
ers form the Peptide-7-Exporter family in the Transport Classifi-
cation Database and are collectively referred to as BceAB-type
systems (13, 14). They are usually found in the genetic neighbor-
hood of a two-component regulatory system (TCS; BceRS type)
that controls expression of the transporter operon (15, 16). Im-
portantly, these transporters not only mediate resistance but play
an additional role as sensors, because the TCSs alone are unable to
detect their substrate peptides (11, 17). Together, transporters and
TCSs form peptide antibiotic resistance modules and are found
widely distributed among low-GC Gram-positive organisms
(13, 16). A comparative genomics analysis identified two BceAB-
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type transporters in the genome of E. faecalis (16), but no func-
tional data are available on these systems, nor has a TCS been
identified as the corresponding regulator.
In accordance with the need for a better understanding of the
response of E. faecalis to antibiotics that inhibit cell wall synthesis,
a recent transcriptomic study identified a large number of genes
that were upregulated after exposure to ampicillin, cephalothin,
vancomycin, and bacitracin (8). Of these compounds, bacitracin
elicited the broadest response, affecting genes with functions in
cell wall maintenance, metabolism, and transport processes. Here
we report on a proteomic analysis of the bacitracin response of E.
faecalis. Among the differentially produced proteins, we again
identified those involved in cell wall maintenance and energy me-
tabolism as important factors. Additionally, one BceAB-type
transporter was found at higher levels following bacitracin expo-
sure, and subsequent investigations revealed the existence of a
regulatory and resistance network comprised of two such trans-
porters and one TCS.
MATERIALS AND METHODS
Bacterial strains and growth conditions. All bacterial strains and plas-
mids used in this study are listed in Table S1 in the supplemental material.
E. coli MC1061 was used for cloning with vector pTCVlac; strains DH5
and XL1-Blue were used for all other cloning. E. coli and B. subtilis were
grown routinely in Luria-Bertani (LB) medium at 37°C with agitation
(200 rpm). Enterococcus faecalis was grown routinely in brain heart infu-
sion (BHI) at 37°C without agitation. E. faecalis was transformed by elec-
troporation as previously described (18). B. subtilis was transformed by
natural competence as previously described (19). Selective media con-
tained ampicillin (100gml1), chloramphenicol (10gml1 for E. coli;
15 g ml1 for E. faecalis; 5 g ml1 for B. subtilis), kanamycin (50 g
ml1 for E. coli; 1,000 g ml1 for E. faecalis), 1 g ml1 erythromycin
with 25gml1 lincomycin (formacrolide-lincosamide-streptograminB
[MLS] resistance), or spectinomycin (150 g ml1 for E. faecalis; 100 g
ml1 for B. subtilis). Bacitracin was supplied as the Zn2 salt. Solid media
contained 1.5% (wt/vol) agar. Growth was measured as optical density at
600 nm (OD600).
Proteomic analysis. For proteomic analyses, exponentially growing
cultures (OD600 0.4) ofE. faecalisV583 inBHImediumwere exposed to
64 g ml1 bacitracin for 1 h. The cytoplasmic protein fraction was ex-
tracted and analyzed by isoelectric focusing, followed by second-dimen-
sion (2D) SDS-PAGE. Differentially produced proteins were identified by
mass spectrometry. Detailed experimental and analytical procedures are
described in the supplemental text.
Construction of plasmids and genetic techniques. All primer se-
quences used for cloning or transcriptional start site mapping are listed in
Table S2 in the supplemental material.
Transcriptional promoter fusions to lacZ in E. faecalis were con-
structed in the vector pTCV-lac (20). All fragments were cloned via the
EcoRI andBamHI sites of the vector. The exact regions amplified aswell as
the primers used are given in Tables S1 and S2 in the supplemental mate-
rial. For complementation of the strain of E. faecaliswith a deletion of the
transporter operon EF2050-2049, the entire operon, including its native
promoter region, was cloned into the EcoRI and BamHI sites of vector
pAT28 (21). Transcriptional promoter fusions in B. subtilis of EF2752
(PEF2752) or EF2050 (PEF2050) to the bacterial luciferase genes (luxAB-
CDE) were cloned into the EcoRI and SpeI sites of the vector pAH328
(22), creating plasmids pCF135 and pCF134. The exact regions contained
in the construct are given in Table S1 in the supplemental material.
Plasmids for heterologous, xylose-inducible expression of EF2752-
2751 or EF2050-2049 in B. subtilis (pCF129 and pCF130) were con-
structed in the vector pXT using the BamHI and EcoRI restriction sites,
placing the genes under the control of the vector’s xylA promoter (23).
The construct for the heterologous expression of EF0926-0927 in B.
subtilis was cloned according to the BioBrick standard (24). To facilitate
constitutive expression in B. subtilis, a BioBrick of the bceRS operon pro-
moter, PbceR, of B. subtilis was amplified and cloned into the EcoRI and
SpeI sites of vector pSB1A3, creating pCF144. A BioBrick of EF0926-0927
containing an optimal Shine-Dalgarno sequence for B. subtilis was simi-
larly cloned into pSB1A3 via EcoRI and SpeI, creating plasmid pCF143.
Assembly of both BioBricks in vector pBS2E (25) created plasmid
pCF145, where expression of EF0926-0927 is controlled by PbceR.
Constructs for unmarked gene deletions in E. faecalis were cloned in
the vector pLT06 (26). For each gene or operon to be deleted, 700- to
1,000-bp fragments located immediately before the start codon of the first
gene (“up” fragment) and after the stop codon of the last gene (“down”
fragment) were amplified. The primers were designed to create a 17- to
20-bp overlap between the PCR products (see Table S2 in the supplemen-
talmaterial), facilitating fusion of the fragments by PCRoverlap extension
(27) and subsequent cloning into pLT06. Gene deletions were performed
as previously described (26).
All constructs were checked for PCR fidelity by sequencing, and all
created strains were verified by PCR using appropriate primers.
To determine the transcriptional start sites of the EF2050-2049 and
EF2752-2751 operons, total RNAwas isolated from E. faecalis JH2-2 using
a RNeasy minikit and QIAshredder columns (Qiagen) according to the
manufacturer’s instructions. DNA was removed with a TURBO DNA-
free kit (Ambion). Transcriptional start sites were determined by 5= rapid
amplification of cDNA ends (5= RACE) as described previously (28). The
sets of nested primers used are listed in Table S2 in the supplemental
material.
Antimicrobial susceptibility assays. For antibiotic susceptibility as-
says, all cultures were grown in Mueller-Hinton (MH) medium. MICs of
bacitracin were determined by broth dilution assays. Freshly grown colo-
nies of E. faecalis were suspended in sterile saline to 0.5 McFarland stan-
dard turbidity and diluted 1:1,000 into MH medium containing serial
2-fold dilutions of bacitracin. For B. subtilis, freshly grown overnight cul-
tures in MH broth were used as inoculum at a dilution of 1:500. After 24
h of incubation, theMICwas scored as the lowest concentration where no
growth was observed. MICs obtained from broth dilution assays were
subsequently confirmed using bacitracin Etest strips (bioMérieux) ac-
cording to the manufacturer’s instructions.
Additionally, bacitracin susceptibility of B. subtilis was determined by
growth inhibition of exponentially growing cultures in LB. Strains were
inoculated 1:500 fromovernight cultures and grown in 100-l volumes in
a 96-well plate. Cultures were incubated at 37°C with shaking (medium
intensity) in a Synergy2 multimode microplate reader from BioTek con-
trolled by the softwareGen5, andOD600wasmonitored every 5min. At an
OD600 of 0.02 (4 to 5 doublings since inoculation; corresponding to an
OD600 of 0.1 in cuvettes with a 1-cm light path length), bacitracin was
added to a final concentration of 2, 4, 8 or 16 g ml1 with one well left
untreated, and growth was monitored for another 2.5 h.
-Galactosidase assays. Qualitative assays for induction of LacZ re-
porter constructs in E. faecalis were performed by the disk diffusion
method. A suspension of cells from freshly grown colonies at 0.5 Mc-
Farland standard turbidity was spread onto MH agar containing appro-
priate antibiotics for selection and 5-bromo-4-chloro-3-indolyl--D-
galactopyranoside (X-Gal) (100g ml1) using cotton swabs. Filter discs
containing 5 l antibiotic test solution (100 mg ml1) were placed onto
the plates. After overnight incubation, plates were scored for formation of
a blue ring around the filter discs.
For quantitative assays, exponentially growing cells in BHI me-
dium were exposed to different concentrations of bacitracin for 1 h as
previously described (2). -Galactosidase activities were assayed in
permeabilized cells as described previously and were expressed in
Miller units (MU) (29, 30).
Luciferase assays. Luciferase activities of B. subtilis strains containing
pCF135 and pCF134 were assayed using the microplate reader described
above. LB medium was inoculated 1:500 from overnight cultures, and
Gebhard et al.
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each strain was grown in 100-l volumes in a 96-well plate. Cultures were
incubated at 37°C with shaking (medium intensity), and the OD600 was
monitored every 10 min. At an OD600 of 0.02 (see above), bacitracin was
added to a final concentration of 1, 3, or 10 g ml1, with one well left
untreated. Cultures were further incubated for 2 h, and the OD600 and
luminescence (endpoint reads; 1-s integration time; sensitivity, 200) were
monitored every 5 min. OD600 values were corrected using wells contain-
ing 100 l LB medium as blanks. Raw luminescence output (relative
luminescence units [RLU]) was normalized to cell density by dividing
each data point by its corresponding corrected OD600 value (RLU/OD).
RESULTS
Proteome analysis of the bacitracin stress response of E. faeca-
lis. To investigate the response of E. faecalis to bacitracin, we an-
alyzed the proteome of strain V583, whose genome has been fully
sequenced, after 1 h exposure to 64 g ml1 bacitracin, which
corresponded to the strain’s MIC, compared to an untreated con-
trol. A detailed description of the findings is presented in the sup-
plemental text. The 2D gels and detailed analyses of protein spots
are available in Fig. S1 and in Tables S3 and S4, respectively, in the
supplemental material. In brief, as expected, a number of proteins
involved in cell wall metabolism were found in increased quanti-
ties after bacitracin stress. Additionally, several enzymes for en-
ergy metabolism or fatty acid synthesis were differentially ex-
pressed, indicating metabolic rearrangements in response to
bacitracin. Further proteins with increased production after bac-
itracin exposure likely indicated a general response to stress. The
twomost strongly upregulated proteins are homologous to a pro-
tein of unknown function, YvlB of B. subtilis, and to cobyric acid
synthase. Their roles in the response to bacitracin are not clear.
The third strongest effect was observed with EF2050. This protein
is the ATPase component of a BceAB-like ABC transporter
(EF2050-2049), a group of proteins that to date have been identi-
fied only in the context of resistance against peptide antibiotics
(13, 16). As mentioned above, operons for two such transporters
were previously identified in the genome of E. faecalis by a com-
parative genomics study, namely, EF2050-2049 and EF2752-2751
(16). Although our proteomic study identified only the former
transporter, both loci were found to be upregulated in response to
bacitracin by transcriptome analysis (8). We therefore decided to
investigate these two transporters in more detail, regarding both
their role in bacitracin resistance and their regulation.
Identification of orthologous genes in E. faecalis JH2-2. Be-
cause strain V583 is a vancomycin-resistant clinical isolate, we
chose the laboratory strain JH2-2 for all further studies. For this,
we first needed to identify the genes corresponding to EF2050-
2049 and EF2752-2751 from strain V583. Using PCR primers de-
signed according to the V583 genome sequence, we readily ob-
tained amplicons of the correct size from strain JH2-2. DNA
sequencing confirmed that all four genes possessed the same se-
quence in both strains. For simplicity and consistency with the
existing literature, we maintained the strain V583 nomenclature
for all genes from strain JH2-2 throughout this study.
As described in the introduction, BceAB-type transporters are
usually regulated by a BceRS-like TCS encoded in the genomic
neighborhood of the transporter. However, neither of the two
transporters investigated here possessed such a regulatory system.
Because the sensor kinases of these TCSs have a characteristic
domain architecture of two transmembrane helices with a very
short intervening extracellular linker (ca. 3 to 10 amino acids) and
no additional cytoplasmic domains besides the catalytic domains
for autophosphorylation, candidate TCSs can be identified via
genome analyses (16). Indeed, the genome of E. faecalis V583 en-
codes a single BceRS-like TCS, EF0926-0927, and identical genes
were identified by PCR and sequencing in strain JH2-2. Schemat-
ics of all three loci are shown in Fig. 1.
The transporter EF2050-2049, which was identified as bacitra-
cin induced in our proteome analysis, is amember of phylogenetic
group VII of BceAB-type transporters, which also includes the
YxdLMsystemofB. subtilis (16). The second transporter, EF2752-
2751, could not be assigned to any group. However, its branch of
the phylogenetic tree includes four other transporters, one fromE.
faecium and three from Lactobacillus species (16), showing that
the occurrence of close homologues is not restricted to E. faecalis.
Interestingly, one of these transporters was recently shown to be
involved in nisin resistance of Lactobacillus casei (31).
Both transporters are induced by bacitracin.To confirmbac-
itracin-induced expression of the transporter operon EF2050-
2049, and to test if EF2752-2751 was also inducible under these
conditions, we first constructed transcriptional fusions of the pro-
moter regions PEF2050 and PEF2752 to a lacZ reporter gene. The
transcriptional start sites of both operons were determined by 5=
RACE, and putative 10 and 35 promoter elements could be
identified within a suitable distance upstream of the1 position
(Fig. 1A). Additionally, sequence analysis of the regions upstream
of the35 element revealed the presence of inverted repeats with
FIG 1 Schematic of operon structures and promoter regions in the resistance
circuit. (A) Operons for the ABC transporters. In each, the first gene encodes
the ATPase and the second gene the permease; the bent arrow indicates the
promoter. The nucleotide sequences of the promoter regions are given below
the respective schematics. The proposed response regulator binding site is
highlighted in gray, the10 and35 elements are boxed, the transcriptional
start site (1) determined by 5=RACE is shown as an underlined capital letter,
and the translational start is shown in italicized capitals. Vertical lines show the
beginning of fragments used to construct transcriptional reporter fusions, and
the numbers of the derived constructs are given. (B) Operon for the two-
component system. The first gene encodes the response regulator, and the
second gene encodes the sensor kinase; the promoter region is indicated by a
bent arrow. No putative regulator binding site was identified in the promoter,
and therefore no sequence is shown.
Bacitracin Resistance Network of E. faecalis
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similarity to the binding consensus of BceR-like regulators (16)
(Fig. 1A). The transcriptional fusions were therefore designed to
contain all of these motifs (fragments 56 for PEF2050 and 59 for
PEF2752 [Fig. 1A]).
Initial assays were performed by disc diffusion on agar plates
inoculated with a lawn of the reporter strains. Consistent with the
proteome analysis, blue circles indicating promoter induction
were observed around filter discs containing bacitracin (data not
shown). Because BceAB-like transporters normally recognize sev-
eral different substrates (12, 13, 17), we also tested several other
cell wall-active antibiotics. Nisin, gallidermin, vancomycin, teico-
planin, and penicillin G did not elicit a response, but the lantibi-
otic mersacidin was able to induce both promoters (data not
shown). These results were confirmed by quantitative -galacto-
sidase assays in liquid cultures and showed that maximum induc-
tion of both promoters was obtained at 20 to 50gml1 mersaci-
din or 4 g ml1 bacitracin but not with any of the other
antibiotics tested (Fig. 2A and data not shown). Because mersaci-
din is not commercially available and bacitracin elicited the more
sensitive response, all subsequent assays were performed using
bacitracin as an inducer. Following 1 h exposure of exponentially
growing cultures to 4 g ml1 bacitracin, PEF2050-lacZ was in-
duced approximately 5-fold from23Miller units (MU) to 112MU
(Fig. 2A, left). PEF2752-lacZwas also induced by bacitracin, but the
overall activities were low (2 to 4 MU) and induction was only
2-fold (Fig. 2B, right), explaining why this transporter had not
been identified in the proteome analysis.
Next, we constructed a series of truncated promoter fusions
lacking part of (fragment 57) or the entire (fragments 58 and 60)
proposed regulator binding sites (Fig. 1A). All strains carrying the
derived promoter-lacZ fusions displayed activities near the detec-
tion limit (ca. 1 MU) and no induction by bacitracin (Fig. 2A),
showing that these sequences were required for expression and
thus indeed presented likely binding sites for a BceR-like regula-
tor.
Both transporters and the TCS are required for full bacitra-
cin resistance of E. faecalis. To investigate the role of the two
transporters in bacitracin resistance, we created unmarked dele-
tions of the entire coding region of each transporter. Additionally,
the gene for the sensor kinase, EF0927, was deleted. Despite re-
peated attempts, no deletion of the regulator gene EF0926 could
be achieved. All three deletion strains displayed reduced bacitra-
cin resistance compared to the wild-type strain JH2-2, albeit to
different extents (Table 1). The strongest effect with a 2- to 4-fold-
increased sensitivity was observed for EF2050-2049, while dele-
tion of EF2752-2751 and of EF0927 resulted in changes of only up
to 2-fold in theMIC. The veryminor effect of the EF0927 deletion
strain can possibly be explained by deletion of the sensor kinase
alone with the regulator still present, as discussed in more detail
below. Interestingly, deletion of both transporters simultaneously
did not further reduce the MIC compared to deletion of EF2050-
2049 alone. The lack of an additive effect might suggest that both
transporters participate in the same pathway, rather than acting
independently of each other. Importantly, none of the deletion
FIG 2 Induction of the transporter operons by bacitracin. Promoter regions of the transporter operons EF2050-2049 (left) and EF2752-2751 (right) were fused
to lacZ, and resulting strains of E. faecalis JH2-2 were assayed for -galactosidase activity, expressed in Miller units (MU), after 1 h exposure of exponentially
growing cultures to 0gml1 (white bars) or 4gml1 (gray bars) bacitracin. (A) Successive truncations from the 5= end of the promoter region. Bars are labeled
by the number of each construct, as shown in Fig. 1. Constructs 56 and 59 contain the full promoter region. (B) Full-length constructs of the promoter fusions
from panel A assayed in the wild-type (WT; same data as in panel A) and mutant backgrounds. The genes deleted in each strain are indicated by the locus tags
below the bars. Results are means plus standard deviations for three to four biological replicates. The significance of induction was calculated for each strain by
one-tailed, pairwise t test analysis and is indicated by one (P 0.05), two (P 0.005), or three (P 0.001) asterisks. ns, not significant.
Gebhard et al.
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strains displayed a growth defect compared to the wild-type strain
(Table 1), showing that the differences in MIC were specifically
due to loss of resistance determinants and not to altered growth
kinetics. Complementation of the EF2050-2049 deletion mutant
by supplying the transporter operon in trans (strain DLEf16) re-
stored bacitracin resistance (Table 1). The higher MIC compared
to the wild-type strain is most likely due to the increase in copy
number by the plasmid-based complementation strategy and sup-
ports the role of EF2050-2049 in bacitracin resistance ofE. faecalis.
Transporters and TCS form a regulatory network. BceAB-
type transporters are often required for their own regulation by
acting as the actual sensors of antimicrobial peptides that some-
how communicate with the TCS to trigger activation of the signal-
ing cascade (11, 17). In such cases, expression of the transporter
operon is abolished in strains carrying transporter deletions (11,
12, 32). In some bacteria, exemplified by Staphylococcus aureus,
two separate transporters exist, where one acts as the sensor, while
the second is responsible for resistance (17, 32). We therefore
wanted to investigate the role of the two enterococcal transporters
in regulation of their own promoters. Additionally, the TCS
EF0926-0927 had so far only been implicated in regulation of the
transporters based on sequence predictions, which had to be val-
idated experimentally.
Deletion of the sensor kinase EF0927 drastically reduced the
expression levels of PEF2050-lacZ to less than 20% of wild-type
activities (Fig. 2B, left). Interestingly, a significant induction by
bacitracin could still be observed, whichwas again likely due to the
presence of the response regulator as described below. Expression
of PEF2752-lacZ was also reduced by deletion of the sensor kinase,
but due to the overall low activities of this reporter, the differences
were less pronounced. Nevertheless, the significant induction by
bacitracin observed in the wild type was lost in the EF0927 dele-
tion strain (Fig. 2B, right). These data show that the TCS EF0926-
0927 indeed acts as the regulator for both transporter operons.
Deletion of the transporter EF2050-2049 had no effect on ex-
pression of either transporter (Fig. 2B), indicating that this trans-
porter’s role was restricted to mediating resistance. In contrast,
deletion of EF2752-2751 severely reduced the activities of both
lacZ fusions, and bacitracin-dependent induction was lost (Fig.
2B). Thus, the second transporter represents the antibiotic sensor
of the resistance network.
In B. subtilis, expression of BceRS, the TCS regulating bceAB
expression, is not induced by bacitracin (33). However, the ho-
mologous system BraRS from S. aureus (referred to as NsaRS in
reference 34) was shown to be upregulated in response to nisin,
one of its substrate peptides (34). To test if EF0926-0927 was in-
ducible by bacitracin, we constructed a transcriptional fusion of
the promoter PEF0926 to lacZ and introduced it into E. faecalis
JH2-2 and derived deletion strains. Exposure of exponentially
growing cells to bacitracin resulted in a strong upregulation of
promoter activities from 1 to 16 MU (Fig. 3). Interestingly, dele-
tion of neither theTCSnor the two transporters affected promoter
activities or bacitracin-dependent induction (Fig. 3), showing that
regulation of the TCS is mediated by an as-yet-unidentified addi-
tional regulator and not due to autoregulation. Importantly, this
regulation by a factor external to the resistance networkmay offer
an explanation for the mild phenotypes of the EF0927 deletion
strain compared to the transportermutants: in the	EF0927 back-
ground, expression of the response regulator gene EF0926 is still
upregulated in the presence of bacitracin. Because in the absence
of their cognate sensor kinase many response regulators can be
efficiently phosphorylated and thus activated by small-molecule
phospho-donors such as acetyl-phosphate (35, 36), this increased
production of EF0926 may indirectly lead to an induction of its
target promoters by bacitracin.
EF2050-2049 canmediate bacitracin resistance in B. subtilis.
Because of the mild effects of the gene deletions generated in E.
faecalis, we next attempted to transfer parts of the identified resis-
tance network to B. subtilis to confirm the individual roles of the
components in bacitracin resistance. As a chassis, we employed a
strain of B. subtilisW168 carrying unmarked deletions of all three
endogenous Bce-like modules (bceRS-bceAB, psdRS-psdAB, and
yxdJK-yxdLM-yxeA). This strain, TMB1518, has been developed
and validated as an appropriate platform to investigate resistance
mechanisms against inhibitors of cell wall synthesis and the asso-
ciated regulatory pathways from E. faecalis in a genetically highly
accessible set-up (a detailed description will be published else-
where). Expression of the EF2050-2049 operon under the control
of a xylose-inducible promoter increased the MIC for bacitracin
FIG 3 Induction of the two-component system operon by bacitracin. The
promoter region of the two-component system operon EF0926-0927 was
fused to lacZ and introduced intowild-type E. faecalis JH2-2 (WT) andmutant
backgrounds. The resulting strains were assayed for -galactosidase activity,
expressed in Miller units (MU), after 1 h exposure of exponentially growing
cultures to 0 g ml1 (white bars) or 4 g ml1 (gray bars) bacitracin. The
genes deleted in each strain are indicated by locus tags below the bars. Results
are means plus standard deviations for three biological replicates. The signifi-
cance of induction and strain differences was calculated across the entire data
set by two-way analysis of variance (ANOVA). Significant effects of bacitracin
compared to uninduced cells are indicated by three asterisks (P 0.001); the
different mutant backgrounds caused significant differences between strains
(P 0.018; not depicted in the graph).
TABLE 1 Bacitracin sensitivity of E. faecalis strains
Strain or genotype
MIC (g ml1)
Growth rate
(h1)bBroth dilutiona Etest
JH2-2 32 32 1.06
 0.067
	EF0927 16–32 24 1.2
 0.377
	EF2050-2049 8–16 8 1.11
 0.135
	EF2752-2751 16 16 1.14
 0.146
	EF2050-2049 	EF2752-2751 8 8 1.08
 0.033
DLEf16 64 64 ND
a Results are from three independent broth dilution experiments; where a range of
concentrations is given, results varied between replicates.
b Results are means
 standard errors from three to six independent experiments. ND,
not determined.
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of TMB1518 from 2 g ml1 to 4 to 8 g ml1 (from 1 to 1.5 g
ml1 to 3 g ml1 when determined by Etest assays), while ex-
pression of EF2752-2751 was unable to confer any resistance. As
observed before for E. faecalis, the differences in MIC were again
small. We therefore chose a different approach, assaying for
growth inhibition of exponentially growing cultures that were
challenged with increasing antibiotic concentrations, which can
provide a more sensitive assay for cell wall-active antibiotics. B.
subtilis strain TMB1518 as well as its derivative carrying the
EF2752-2751 expression construct were unaffected by 2 g ml1
bacitracin, while 4 g ml1 or 8 g ml1 increasingly inhibited
growth (Fig. 4A and C). In contrast, the strain harboring the ex-
pression construct for EF2050-2049 was not affected by concen-
trations up to 4gml1 and showed only slight growth inhibition
at 8g ml1 (Fig. 4B). Exposure to 16g ml1 caused cell lysis in
all strains tested (Fig. 4). These data confirm that EF2050-2049 is
indeed directly capable of mediating bacitracin resistance, not
only in E. faecalis but also in the heterologous host B. subtilis.
EF2752-2751, on the other hand, is not directly responsible for
bacitracin resistance.
EF2752-2751 and the TCS are sufficient for promoter induc-
tion in B. subtilis. Following the successful transfer of bacitracin
resistance to B. subtilis, we next wanted to test if the regulatory
pathway could also be reconstituted in the heterologous host. To
this end, both target promoters, PEF2050 and PEF2752, were fused to
the bacterial luciferase operon luxABCDE as a reporter (22) and
introduced into TMB1518. Both constructs resulted in basal lucif-
erase activities that were not affected by addition of bacitracin
(Fig. 5, leftmost panels). Thus, no endogenous B. subtilis system
was able to induce either of the promoters. Next, the TCS operon
EF0926-0927 was introduced into the reporter strains, controlled
by the promoter of the homologous bceRS operon of B. subtilis to
ensure appropriate expression levels. The presence of the TCS
alone did not alter the activities of the transporter promoters, and
bacitracin-dependent induction was still not observed (Fig. 5, left
center panels), confirming that the TCS alone is unable to respond
to the peptide, as has been shown for other BceRS-like systems
(11, 12, 32). Additional introduction of the expression construct
for EF2050-2049 also did not change the promoter activities (Fig.
5, right center panels), showing that the encoded transporter has
no sensory function. In contrast, simultaneous presence of the
TCS and the transporter EF2752-2751 increased the basal activi-
ties of the PEF2050-lux reporter, and addition of bacitracin resulted
in a further 2-fold induction (Fig. 5, top rightmost panel). Expres-
sion of PEF2752-luxwas not altered in the same genetic background
(Fig. 5, bottom rightmost panel), consistent with the minor in-
duction observed for this promoter in E. faecalis. These results
clearly show that together, the transporter EF2752-2751 and the
TCS EF0926-0927 constitute the sensory and regulatory compo-
nent of the resistance network and that the second transporter
operon, EF2050-2049, is their main target.
DISCUSSION
Our proteomic analysis of bacitracin-exposed E. faecalis showed
that the bacterium responds to the antibiotic with a specific reac-
tion to the bacitracin-induced cell wall damage, as well as with a
more general response to stress or growth inhibition. Overall, our
data are largely consistent with the findings of a recent transcrip-
tome analysis of E. faecalis treated with different inhibitors of cell
wall synthesis, including bacitracin and vancomycin (8). A de-
tailed comparison of our study and the previous one is presented
in the supplemental text. Together, these two data sets provide a
useful overview of the response of E. faecalis to inhibitors of cell
wall synthesis such as bacitracin.
Among the differentially expressed genes identified from both
studies was a putative ABC transporter, EF2050-2049, which is a
homologue of the bacitracin resistance transporter BceAB of B.
subtilis (11, 33). A second such transporter, EF2752-2751, had been
previously identified in E. faecalis by a comparative genomics anal-
ysis of BceAB-type transporters in Firmicutes bacteria (16).While
this second transporter was not found in our proteomic analysis,
its ATP-binding cassette domain-encoding gene, EF2752, was
slightly induced by bacitracin during the transcriptome study (8).
Additionally, we could identify a TCS of E. faecalis with similarity
to BceRS of B. subtilis, which regulates expression of BceAB (33).
Again, the encoding genes EF0926-0927 had been reported as bac-
itracin inducible and were also found to be induced by the cell
wall-active antibiotics cephalothin and vancomycin (8). Our sub-
sequent characterization of these three gene loci in E. faecalis as
well as heterologously in B. subtilis showed that they act together
and form a resistance network against bacitracin. A schematic of
the derived model is shown in Fig. 6.
The primary sensor of the network is the transporter EF2752-
2751, which communicates the presence of bacitracin to the sen-
FIG 4 Transfer of bacitracin resistance to B. subtilis. Strain TMB1518 (A) and derived strains carrying expression constructs of the transporter operon
EF2050-2049 (B) or EF2752-2751 (C) were grown to exponential phase and challenged with bacitracin, and growth was monitored as optical density (OD600).
The time point of bacitracin addition is indicated by the arrow; concentrations are given in panel A. Representative results of two or three independent
experiments are shown. Experimentswere carried out in a 100-l culture volume in 96-well plates; thus,ODvalues cannot be directly compared tomeasurements
made in cuvettes with a 1-cm light path length.
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sor kinase EF0927. Activation of the sensor kinase and phospho-
transfer to the response regulator EF0926 then leads to activation
of the main target promoter, PEF2050, and increased production of
the transporter EF2050-2049. This transporter then removes the
bacitracin from its site of action, thus ensuring resistance. Simul-
taneously, expression of the sensory transporter is slightly induced
by the TCS, while expression of the TCS operon is induced by an
as-yet-unidentified regulator that is not directly part of the resis-
tance network. Upregulation of a BceRS-like TCS has so far been
reported only for the BraRS ( NsaRS) system of S. aureus (34)
and may lead to an increased sensitivity or stronger induction of
the resistance transporter. Future studies will be directed at iden-
tification of the regulator for the TCS. Because the transcriptome
study showed the TCS to be inducible by three of four tested
inhibitors of cell wall biosynthesis (8), it appears likely that this
regulation is part of the cell envelope stress response of E. faecalis.
A number of candidate regulatory systems have been identified by
comparative genomics and provide a good starting point for sub-
sequent investigations (37).
Several BceRS-BceAB-type resistancemodules have been char-
acterized in detail and were always shown to be involved in pep-
tide antibiotic resistance (13, 17). Importantly, the TCSs always
rely on one of the transporters for stimulus perception and are
unable to induce their target genes in the absence of their trans-
porter (11, 12, 31, 32, 38). In most cases the transporter and TCS
are encoded in adjacent operons (15, 16), but in S. aureus and
Lactobacillus casei, some TCSs were shown to regulate the expres-
sion of a second transporter encoded elsewhere on the chromo-
some (31, 32). The situation in E. faecalis as identified in the pres-
ent study is even more complex, with not only the target
transporter but also the sensory transporter being encoded in a
different locus from the TCS. To our knowledge, this is the first
report where a regulatory interaction between a BceAB-like trans-
porter and BceRS-like TCS was shown for two systems not en-
coded together. Our findings further emphasize the widespread
occurrence of these resistance modules and show that the regula-
tory paradigm is conserved even if genomic arrangement is not.
As mentioned in the introduction, E. faecalis is likely exposed
to a range of antimicrobial peptides in the gastrointestinal tract of
humans and animals, which can be of host origin or produced by
other bacteria of the gut microflora. This raises a question regard-
ing the physiological substrate of the resistance network described
here. Most Bce-like modules analyzed so far are not specific for a
single substrate but instead recognize a range of often structurally
diverse peptides (17). In S. aureus, the human beta-defensin hBD3
and cathelicidin LL-37 have been identified as substrates of the
ApsRS-VraFGmodule (39), showing that the function of Bce-like
modules is not restricted to bacterially derived antimicrobial pep-
tides. Our initial screening experiments identified the lantibiotic
mersacidin as a second inducer of both enterococcal transporters,
and it is possible or even likely that other substrates exist. Partic-
ularly for a gut bacterium like E. faecalis, it will be interesting to
FIG 5 Functional reconstitution of the regulatory circuit in B. subtilis. Promoter regions of the transporter operons EF2050-2049 (top graphs) and EF2752-2751
(bottom graphs) were fused to luxABCDE and introduced into B. subtilis TMB1518. Additionally, the two-component system and transporter operons were
introduced under the control of a constitutive (PbceR) or xylose-inducible (Pxyl) promoter. The expression constructs present in each strain are illustrated above
the graphs, using the same shading as in Fig. 1. Exponentially growing cultures were exposed to different concentrations of bacitracin, given in the top leftmost
graph, and luminescence normalized to optical density (RLU/OD) was monitored over 60 min. Results are means plus standard deviations for two or three
biological replicates.
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test if any human antimicrobial peptides can induce expression of
the transporters identified here and if the resistance network im-
parts a selective advantage to the bacterium in the intestinal envi-
ronment.
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